Thrive Earlier Detection envisions a future in which blood drawn at an annual physical is used to find early-stage cancer. Exact Sciences acquired Thrive for up to $2.15B in 2021.

Thrive combines cutting-edge liquid biopsy technology with a machine learning engine to find multiple cancer types from a single blood draw — including many cancers that lack effective screening tools such as ovarian, pancreatic, liver cancers and others.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2020
  • Acquired by EXAS: 2021

• Founders

  • Kenneth W. Kinzler, Ph.D.
  • Nickolas Papadopoulos, Ph.D.
  • Bert Vogelstein, M.D.

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • We're excited to officially be part of the Exact family and work together to make #EarlierDetection of cancer a par… https://t.co/SQVoExQ6SW@ThriveDetect - 02:45 PM Jan 5th
  • Wishing all of our Thrivers a relaxing holiday break to recharge and gear up for a great 2021. Happy Holidays! https://t.co/CZoJKBILRn@ThriveDetect - 02:25 PM Dec 22nd
  • This year, Thrive is contributing to @familyreach's "Hope for the Holidays," a program that provides cancer familie… https://t.co/8imAUBTKgq@ThriveDetect - 04:17 PM Dec 17th